In the past week, AZN stock has gone down by -0.88%, with a monthly decline of -3.30% and a quarterly plunge of -3.84%. The volatility ratio for the week is 1.72%, and the volatility levels for the last 30 days are 1.45% for Astrazeneca plc ADR The simple moving average for the past 20 days is -3.08% for AZN’s stock, with a -2.43% simple moving average for the past 200 days.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
Astrazeneca plc ADR (NASDAQ: AZN) has a higher price-to-earnings ratio of 27.90x compared to its average ratio, The 36-month beta value for AZN is at 0.36. Analysts have varying views on the stock, with 6 analysts rating it as a “buy”, 4 rating it as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for AZN is 3.10B, and currently, shorts hold a 0.24% of that float. The average trading volume for AZN on July 07, 2025 was 5.33M shares.
AZN stock’s latest price update
The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has plunged by -2.36% when compared to previous closing price of $71.13, but the company has seen a -0.88% decline in its stock price over the last five trading sessions. zacks.com reported 2025-07-04 that AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Analysts’ Opinion of AZN
Many brokerage firms have already submitted their reports for AZN stocks, with Exane BNP Paribas repeating the rating for AZN by listing it as a “Outperform”. The predicted price for AZN in the upcoming period, according to Exane BNP Paribas is $75 based on the research report published on April 15, 2025 of the current year 2025.
AZN Trading at -1.78% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.79% of loss for the given period.
Volatility was left at 1.45%, however, over the last 30 days, the volatility rate increased by 1.72%, as shares sank -4.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.33% upper at present.
During the last 5 trading sessions, AZN fell by -0.88%, which changed the moving average for the period of 200-days by -11.27% in comparison to the 20-day moving average, which settled at $71.66. In addition, Astrazeneca plc ADR saw -10.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Astrazeneca plc ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.19% for the present operating margin
- 0.81% for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.14%. The total capital return value is set at 0.14%. Equity return is now at value 19.81%, with 7.45% for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 0.77. The interest coverage ratio of the stock is 7.95.
Currently, EBITDA for the company is 15.44 billion with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 4.45. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.90.
Conclusion
In conclusion, Astrazeneca plc ADR (AZN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
